Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent

Regen BioPharma Inc

Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.
KCL Therapeutics subsidiary awarded U.S. Patent No. 11,324,719 for small molecule NR2F6 agonists/antagonists.
Shares issued under Section 4(a)(2) exemption without underwriters or general solicitation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.